Steroid-Responsive Encephalitis in Coronavirus Disease 2019.
Andrea PilottoSilvia OdoliniStefano MasciocchiAgnese ComelliIrene VolonghiStefano GazzinaSara NocivelliAlessandro PezziniEmanuele Foca'Arnaldo CarusoMatilde LeonardiMaria P PasoliniRoberto GasparottiFrancesco CastelliNicholas J AshtonKaj BlennowHenrik ZetterbergAlessandro PadovaniPublished in: Annals of neurology (2020)
Coronavirus disease 2019 (COVID-19) infection has the potential for targeting the central nervous system, and several neurological symptoms have been described in patients with severe respiratory distress. Here, we described the case of a 60-year-old patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but only mild respiratory abnormalities who developed an akinetic mutism attributable to encephalitis. Magnetic resonance imaging was negative, whereas electroencephalography showed generalized theta slowing. Cerebrospinal fluid analyses during the acute stage were negative for SARS-CoV-2, positive for pleocytosis and hyperproteinorrachia, and showed increased interleukin-8 and tumor necrosis factor-α concentrations. Other infectious or autoimmune disorders were excluded. A progressive clinical improvement along with a reduction of cerebrospinal fluid parameters was observed after high-dose steroid treatment, thus arguing for an inflammatory-mediated brain involvement related to COVID-19. ANN NEUROL 2020;88:423-427.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- cerebrospinal fluid
- sars cov
- high dose
- magnetic resonance imaging
- drug induced
- multiple sclerosis
- cancer therapy
- liver failure
- case report
- rheumatoid arthritis
- computed tomography
- cerebral ischemia
- respiratory tract
- transcranial magnetic stimulation
- respiratory failure
- stem cell transplantation
- resting state
- human health
- magnetic resonance
- neural network
- drug delivery
- contrast enhanced
- risk assessment
- climate change
- subarachnoid hemorrhage
- high frequency